Gene transduction efficiency and maturation status in mouse bone marrow-derived dendritic cells infected with conventional or RGD fiber-mutant adenovirus vectors

Cancer Gene Therapy

Volumn 10, Issue 5, 2003, Pages 421-431

  Okada, Naoki ^a   Masunaga, Yasushige ^a   Okada, Yuka ^b   Iiyama, Sayaka ^a   Mori, Naoki ^a   Tsuda, Takashi ^a   Matsubara, Asako ^a   Mizuguchi, Hiroyuki ^c   Hayakawa, Takao ^c   Fujita, Takuya ^a   Yamamoto, Akira ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^b MUKOGAWA WOMEN'S UNIVERSITY   (Japan)

^c NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

Author keywords

Adenovirus vector; Antigen presentation; Dendritic cell; Gene transduction efficiency; Maturation

Indexed keywords

ADENOVIRUS VECTOR; B7 ANTIGEN; BETA GALACTOSIDASE; CD40 ANTIGEN; CD86 ANTIGEN; CHEMOKINE RECEPTOR CCR6; CHEMOKINE RECEPTOR CCR7; GLYCOPROTEIN GP 100; INTERLEUKIN 12; LIPOPOLYSACCHARIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANIMAL CELL; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; BONE MARROW; CELL ACTIVITY; CELL DIFFERENTIATION; CELL MATURATION; CELLULAR IMMUNITY; DENDRITIC CELL; DOWN REGULATION; GENE EXPRESSION; GENE INSERTION; GENETIC TRANSDUCTION; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSGENE; UPREGULATION; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, CD; BONE MARROW; CELL DIFFERENTIATION; CYTOKINES; DENDRITIC CELLS; ENDOCYTOSIS; GENETIC VECTORS; MICE; MICE, INBRED C57BL; MUTATION; OLIGOPEPTIDES; TRANSDUCTION, GENETIC; TRANSGENES;

ADENOVIRIDAE; ANIMALIA; INSERTION SEQUENCES;

EID: 12444262198     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700586     Document Type: Article

References (58)

1. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245-252.
2. Steinman RM, Inaba K, Turley S, et al. Antigen capture, processing, and presentation by dendritic cells: recent cell biological studies. Hum Immunol. 1999;60:562-567.
3. Mellman I, Steinman RM. Dendritic cells: specialized and regulated antigen processing machines. Cell. 2001;106:255-258.
4. Thurner B, Haendle I, Roder C, et al. Vaccination with MAGE-3AI peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med. 1999;190:1669-1678.
5. Lodge PA, Jones LA, Bader RA, et al. Dendritic cell-based immunotherapy of prostate cancer: immune monitoring of a phase II clinical trial. Cancer Res. 2000;60:829-833.
6. Yu JS, Wheeler CJ, Zeltzer PM, et al. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res. 2001;61:842-847.
7. + T-cell response to dendritic cells genetically engineered to express the MART-1/Melan-A gene. Cancer Res. 1998;58:5305-5309.
8. Ribas A, Butterfield LH, McBride WH, et al. Characterization of antitumor immunization to a defined melanoma antigen using genetically engineered murine dendritic cells. Cancer Gene Ther. 1999;6:523-536.
9. Cao X, Zhang W, He L, et al. Lymphotactin gene-modified bone marrow dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity. J Immunol. 1998;161:6238-6244.
10. Curiel-Lewandrowski C, Mahnke K, Labeur M, et al. Transfection of immature murine bone marrow-derived dendritic cells with the granulocyte-macrophage colony-stimulating factor gene potently enhances their in vivo antigen-presenting capacity. J Immunol. 1999;163:174-183.
11. Melero I, Duarte M, Ruiz J, et al. Intratumoral injection of bone-marrow derived dendritic cells engineered to produce interleukin-12 induces complete regression of established murine transplantable colon adenocarcinomas. Gene Ther. 1999;6:1779-1784.
12. + T cells. Nat Med. 2000;6:1154-1159.
13. Kirk CJ, Hartigan-O'Connor D, Nickoloff BJ, et al. T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: augmentation of dendritic cell-based immunotherapy. Cancer Res. 2001;61:2062-2070.
14. Diebold SS, Lehrmann H, Kursa M, et al. Efficient gene delivery into human dendritic cells by adenovirus polyethylenimine and mannose polyethylenimine transfection. Hum Gene Ther. 1999;10:775-786.
15. Tillman BW, Hayes TL, DeGruijl TD, et al. Adenoviral vectors targeted to CD40 enhance the efficacy of dendritic cell-based vaccination against human papilloma virus 16-induced tumor cells in a murine model. Cancer Res. 2000;60:5456-5463.
16. Rea D, Havenga MJ, van Den Assem M, et al. Highly efficient transduction of human monocyte-derived dendritic cells with subgroup B fiber-modified adenovirus vectors enhances transgene-encoded antigen presentation to cytotoxic T cells. J Immunol. 2001;166:5236-5244.
17. Bergelson JM, Cunningham JA, Droguett G, et al. Isolation of a common receptor for coxsackie B virus and adenovirus 2 and 5. Science. 1997;275:1320-1323.
18. Roelvink PW, Lizonova A, Lee JG, et al. The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F. J Vivol. 1998;72:7909-7915.
19. Roelvink PW, Mi Lee G, Einfeld DA, et al. Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae. Science. 1999;286:1568-1571.
20. 5 promote adenovirus internalization but not virus attachment. Cell. 1993;73:309-319.
21. 5 selectively promotes adenovirus mediated cell membrane permeabilization. J Cell Biol. 1994;127:257-264.
22. Mathias P, Wickham T, Moore M, et al. Multiple adenovirus serotypes use alpha v integrins for infection. J Virol. 1994,68:6811-6814.
23. Wang K, Guan T, Cheresh DA, et al. Regulation of adenovirus membrane penetration by the cytoplasmic tail of integrin β5. J Virol. 2000;74:2731-2739.
24. Okada N, Tsukada Y, Nakagawa S, et al. Efficient gene delivery into dendritic cells by fiber-mutant adenovirus vectors. Biochem Res Commun. 2001;282:173-179.
25. Okada N, Saito T, Masunaga Y, et al. Efficient antigen gene transduction using Arg-Gly-Asp fiber-mutant adenovirus vectors can potentiate anti-tumor vaccine efficacy and maturation of murine dendritic cells. Cancer Res. 2001;61:7913-7919.
26. Lutz MB, Kukutsch N, Ogilvie AL, et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods. 1999;223:77-92.
27. Mizuguchi H, Koizumi N, Hosono T, et al. A simplified system for constructing recombinant adenoviral vectors containing heterologous peptides in the HI loop of their fiber knob. Gene Therapy. 2001;8:730-735.
28. Mizuguchi H, Kay MA, Hayakawa T. Approaches for generating recombinant adenovirus vectors. Adv Drug Deliv Rev. 2001;52:165-176.
29. Mizuguchi H, Kay MA. Efficient construction of a recombinant adenovirus vector by an improved in vitro ligation method. Hum Gene Ther. 1998;9:2577-2583.
30. Mizuguchi H, Kay MA. A simple method for constructing E1- and E1/E4-deleted recombinant adenoviral vectors. Hum Gene Ther. 1999;10:2013-2017.
31. Moore MW, Carbone FR, Bevan MJ. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell. 1988;54:777-785.
32. Pfeifer JD, Wick MJ, Roberts RL, et al. Phagocytic processing of bacterial antigens for class I MHC presentation to T cells. Nature. 1993;361:359-362.
33. Inaba K, Inaba M, Romani N, et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med. 1992;176:1693-1702.
34. Bender A, Sapp M, Schuler G, et al. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. J Immunol Methods. 1996;196:121-135.
35. Arthur JF, Butterfield LH, Roth MD, et al. A comparison of gene transfer methods in human dendritic cells. Cancer Gene Ther. 1997;4:17-25.
36. Li Y, Pong RC, Bergelson JM, et al. Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. Cancer Res. 1999;59:325-330.
37. Stockwin LH, Matzow T, Georgopoulos NT, et al. Engineered expression of the coxsackie B and adenovirus receptor (CAR) in human dendritic cells enhances recombinant adenovirus-mediated gene transfer. J Immunol Methods. 2002;259:205-215.
38. Hammerling GJ, Klar D, Pulm W, et al. The influence of major histocompatibility complex class I antigens on tumor growth and metastasis. Biochim Biophys Acta. 1987;907:245-259.
39. Moller P, Hammerling GJ. The role of surface HLA-A, B, C molecules in tumour immunity. Cancer Surv. 1992;13:101-127.
40. Khanna R. Tumour surveillance: missing peptides and MHC molecules. Immunol Cell Biol. 1998;76:20-26.
41. Mosca PJ, Hobeika AC, Clay TM, et al. A subset of human monocyte-derived dendritic cells expresses high levels of interleukin-12 in response to combined CD40 ligand and interferon-γ treatment. Blood. 2000;96:3499-3504.
42. Schulz O, Edwards AD, Schito M, et al. CD40 triggering of heterodimeric IL-12 p70 production by dendritic cells in vivo requires a microbial priming signal, Immunity. 2000;13:453-462.
43. Ebner S, Ratzinger G, Krosbacher B, et al. Production of IL-12 by human monocyte-derived dendritic cells is optimal when the stimulus is given at the onset of maturation, and is further enhanced by IL-4. J Immunol. 2001;166:633-641.
44. Sallusto F, Schaerli P, Loetscher P, et al. Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation. Eur J Immunol. 1998;28:2760-2769.
45. Lin CL, Suri RM, Rahdon RA, et al. Dendritic cell chemotaxis and transendothelial migration are induced by distinct chemokines and are regulated on maturation. Eur J Immunol. 1998;28:4114-4122.
46. Sozzani S, Allavena P, D'Amico G, et al. Differential regulation of chemokine receptors during dendritic cell maturation: a model for their trafficking properties. J Immunol. 1998;161:1083-1086.
47. Roake JA, Rao AS, Morris PJ, et al. Dendritic cell loss from nonlymphoid tissues after systemic administration of lipopolysaccharide tumor, necrosis factor, and interleukin 1. J Exp Med. 1995;181:2237-2247.
48. Hartmann G, Weiner GJ, Krieg AM. CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. Proc Natl Acad Sci USA. 1999;96:9305-9310.
49. Verdijk RM, Mutis T, Esendam B, et al. Polyriboinosinic polyribocytidylic acid (poly(I:C)) induces stable maturation of functionally active human dendritic cells. J Immunol. 1999;163:57-61.
50. Morelli AE, Zahorchak AF, Larregina AT, et al. Cytokine production by mouse myeloid dendritic cells in relation to differentiation and terminal maturation induced by lipopolysaccharide or CD40 ligation. Blood. 2001;98:1512-1523.
51. Rea D, Schagen FH, Hoeben RC, et al. Adenoviruses activate human dendritic cells without polarization toward a T-helper type 1-inducing subset. J Virol. 1999;73:10245-10253.
52. Hirschowitz EA, Weaver JD, Hidalgo GE, et al. Murine dendritic cells infected with adenovirus vectors show signs of activation. Gene Therapy. 2000;7:1112-1120.
53. Rouard H, Leon A, Klonjkowski B, et al. Adenoviral transduction of human 'clinical grade' immature dendritic cells enhances costimulatory molecule expression and T-cell stimulatory capacity. J Immunol Methods. 2000;241:69-81.
54. Morelli AE, Larregina AT, Ganster RW, et al. Recombinant adenovirus induces maturation of dendritic cells via an NF-κB-dependent pathway. J Virol. 2000;74:9617-9628.
55. Dietz AB, Bulur PA, Brown CA, et al. Maturation of dendritic cells infected by recombinant adenovirus can be delayed without impact on transgene expression. Gene Therapy. 2001;8:419-423.
56. Cyster JG. Chemokines and cell migration in secondary lymphoid organs. Science. 1999;286:2098-2102.
57. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity. 2000;12:121-127.
58. Chen Z, Gordon JR, Zhang X, et al. Analysis of the gene expression profiles of immature versus mature bone marrow-derived dendritic cells using DNA arrays. Biochem Biophys Res Commun. 2002;290:66-72.